Creatine kinase isoenzymes in cerebrospinal fluid in a case of brain damage.

1976 ◽  
Vol 22 (8) ◽  
pp. 1405-1407 ◽  
Author(s):  
P M Bayer ◽  
F Gabl ◽  
G Granditsch ◽  
K Widhalm ◽  
H Zyman ◽  
...  

Abstract We present a case of a 11/2-year-old boy with toxic enteritis, consecutive consumption coagulopathy, and sever brain damage. During the acute phase we found high activity of the BB isoenzyme of creatine kinase in cerebrospinal fluid, but not in the serum. Isoenzyme MM could also be found in the spinal fluid (37.9% of the total activity). We conclude that analysis for creatine kinase isoenzymes in spinal fluid is of clinical importance.

1976 ◽  
Vol 22 (1) ◽  
pp. 63-66 ◽  
Author(s):  
W G Yasmineh ◽  
R B Pyle ◽  
N Q Hanson ◽  
B K Hultman

Abstract We determined the activity of the isoenzymes of creatine kinase in homogenates of fresh tissues from six baboons. Twenty-six tissues were removed from each baboon and the isoenzymes in them were separated by chromatography on diethylaminoethyl-Sephadex A-50. Total activity was greatest in skeletal muscle (2600 U/g wet weight) followed by myocardium (800 U/g), brain (180 U/g), and the bladder and tissues of the gastrointestinal tract (about 100 U/g). Ten tissues had total activities of less than 20 U/g: trachea, lung, kidney, thyroid, gall bladder, liver, spleen, pancreas, common bile duct, and adrenal. Skeletal muscle contained only the MM isoenzyme; myocardium contained 81% MM isoenzyme, 18% MB isoenzyme, and 1% BB isoenzyme. Except for thyroid and pancreas, all other tissues contained mainly the BB isoenzyme. Tissues of the gastrointestinal tract contained significant (7 to 17%) MB isoenzyme activity.


1984 ◽  
Vol 44 (7) ◽  
pp. 611-615 ◽  
Author(s):  
Christer Sylvén ◽  
Eva Jansson ◽  
Anders Kallner ◽  
Kim Böök

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Max Borsche ◽  
Dirk Reichel ◽  
Anja Fellbrich ◽  
Anne S. Lixenfeld ◽  
Johann Rahmöller ◽  
...  

AbstractNeurological long-term sequelae are increasingly considered an important challenge in the recent COVID-19 pandemic. However, most evidence for neurological symptoms after SARS-CoV-2 infection and central nervous system invasion of the virus stems from individuals severely affected in the acute phase of the disease. Here, we report long-lasting cognitive impairment along with persistent cerebrospinal fluid anti-SARS-CoV-2 antibodies in a female patient with unremarkable standard examination 6 months after mild COVID-19, supporting the implementation of neuropsychological testing and specific cerebrospinal fluid investigation also in patients with a relatively mild acute disease phase.


1992 ◽  
Vol 9 (05/06) ◽  
pp. 456-459 ◽  
Author(s):  
Andrew Satin ◽  
Gary Hankins ◽  
Wayne Patterson ◽  
Richard Scott

Sign in / Sign up

Export Citation Format

Share Document